Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.
about
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsClinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Immunomodulatory antibody therapy of cancer: the closer, the betterCo-potentiation of antigen recognition: A mechanism to boost weak T cell responses and provide immunotherapy in vivo.T cell Bim levels reflect responses to anti-PD-1 cancer therapy.B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cellsPD-1 Restrains Radiotherapy-Induced Abscopal Effect.Regulation of host epithelial responses to Cryptosporidium infection by microRNAs.Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1.Multiplex three-dimensional optical mapping of tumor immune microenvironment.CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.High mammographic density in women is associated with protumor inflammation
P2860
Q26797478-F94A4DE5-EADF-4C52-8105-1A83C70BCA95Q34658452-4527C8D5-430B-408D-806E-A826F251A032Q35142851-4D57ED97-284B-4023-98C1-353F97B5E5C8Q36284809-4D88CDC3-0EBB-4BE0-BDB2-C0AB314E3C79Q36891596-4D53D72A-E674-40E3-86CC-41D13BCB7B0BQ37400079-FCA5C512-9A42-4D0F-895F-F8A65CD721E0Q38907646-9C436EEF-15F8-4538-8E0D-89E664181249Q39039251-54C934FF-40CD-4E90-8DE0-FE2A862F04DDQ39090226-231D8ADE-62A5-4DE8-A325-133270CBE70EQ39237785-FD60237B-6E50-4D25-9484-CE0D30A53058Q40297266-46EB7912-D39A-4F81-97A7-43D6B2993FBAQ41591613-CE7AA430-EB61-4B74-AB2B-BFC986A5EE04Q42317483-ADAC8A4C-21B2-4CBA-AC6C-67FA887A1041Q47173153-D3C3469D-BCFE-4717-A453-32100441F98BQ52718482-69B72A0D-E04B-4739-9FD0-0AB9813C1B73Q58793402-C91F2DC5-2205-4A9C-B467-4154CC8B4D2B
P2860
Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endogenous tumor-reactive CD8
@nl
Endogenous tumor-reactive CD8( ...... nable to control tumor growth.
@en
type
label
Endogenous tumor-reactive CD8
@nl
Endogenous tumor-reactive CD8( ...... nable to control tumor growth.
@en
prefLabel
Endogenous tumor-reactive CD8
@nl
Endogenous tumor-reactive CD8( ...... nable to control tumor growth.
@en
P2093
P2860
P356
P1433
P1476
Endogenous tumor-reactive CD8( ...... unable to control tumor growth
@en
P2093
Christopher J Krco
Eugene D Kwon
Rachel M Gibbons
Susan M Harrington
Svetomir N Markovic
P2860
P304
P356
10.4161/ONCI.23972
P577
2013-06-06T00:00:00Z